Ponte; Jose F.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ponte; Jose F..The latest application filed is for "combination therapies employing gitr binding molecules".

Company Profile

2.13.13

Ponte; Jose F. - Weymouth MA
Ponte; Jose F. - South Boston MA
Ponte; Jose F. - Quincy MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies Grant 10,570,209 - Smith , et al. Feb	2020-02-25
Combination Therapies Employing GITR Binding Molecules App 20190030162 - Ponte; Jose F. ; et al.	2019-01-31
GITR Antibodies And Methods Of Inducing Or Enhancing An Immune Response App 20190023799 - Smith; L. Mary ; et al.	2019-01-24
Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies Grant 10,030,074 - Smith , et al. July 24, 2	2018-07-24
Gitr Antibodies And Methods Of Inducing Or Enhancing An Immune Response App 20170137527 - Smith; L. Mary ; et al.	2017-05-18
GITR antibodies and methods of inducing or enhancing an immune response Grant 9,493,572 - Smith , et al. November 15, 2	2016-11-15
Combination Therapies Employing Gitr Binding Molecules App 20160324963 - Ponte; Jose F. ; et al.	2016-11-10
Combination therapies employing GITR binding molecules Grant 9,241,992 - Ponte , et al. January 26, 2	2016-01-26
Gitr Binding Molecules And Uses Therefor App 20150259427 - Smith; L. Mary ; et al.	2015-09-17
Ilt3 Binding Molecules And Uses Therefor App 20150139986 - Ponath; Paul ; et al.	2015-05-21
Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies Grant 9,028,823 - Smith , et al. May 12, 2	2015-05-12
ILT3 binding molecules and uses therefor Grant 8,901,281 - Ponath , et al. December 2, 2	2014-12-02
Combination Therapies Employing Gitr Binding Molecules App 20140220002 - Ponte; Jose F. ; et al.	2014-08-07
Combination therapies employing GITR binding molecules Grant 8,591,886 - Ponath , et al. November 26, 2	2013-11-26
Gitr Binding Molecules And Uses Therefor App 20130183321 - Smith; L. Mary ; et al.	2013-07-18
Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies Grant 8,388,967 - Smith , et al. March 5, 2	2013-03-05
Methods for inducing or enhancing an immune response by administering GITR-binding antibodies App 20110059109 - Smith; L. Mary ; et al.	2011-03-10
Ilt3 Binding Molecules And Uses Therefor App 20110034675 - Ponath; Paul ; et al.	2011-02-10
GITR-binding antibodies Grant 7,812,135 - Smith , et al. October 12, 2	2010-10-12
ILT3 binding molecules and uses therefor Grant 7,777,008 - Ponath , et al. August 17, 2	2010-08-17
Combination therapies employing GITR binding molecules App 20090136494 - Ponath; Paul ; et al.	2009-05-28
ILT3 binding molecules and uses therefor App 20080038260 - Ponath; Paul ; et al.	2008-02-14
ILT3 binding molecules and uses therefor App 20070041982 - Ponath; Paul ; et al.	2007-02-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.